SARS-CoV-2 Spike Antibody IgG&IgM Positive Control (MAb) (CAT#: VAb-Wyb096)
Product Overview
The product contains two isotype antibody clone Human IgG and IgM, which can recognizes SARS-CoV-2 Spike-RBD Protein.
Target
SARS-CoV-2
Source
Cultured in vitro under conditions free from animal derived components.
Clonality
Mab
Specificity
Antibody recognizes SARS-CoV-2 S-RBD Protein
Type
Antibody
Form
Liquid
Buffer Solution
PBS, pH 7.4.
Applications
Used for in vitro diagnostic use in the quality control of serum on clinical chemistry and immunoassay systems.
Storage
Store at -20°C.
Introduction
The 2019 novel coronavirus, or "SARS-CoV-2", was discovered because of Wuhan virus pneumonia cases in 2019, and was named by the World Health Organization on January 12, 2020. It belongs to the beta genera of the Coronaviridae family, together with SARS coronavirus in 2003 and MERS coronavirus in 2012. The alignment between SARS-CoV-2 and 2003 SARS CoV has about 70% sequence similarity and 40% sequence similarity with MERS CoV. The coronavirus genome encodes a spike protein, an envelope protein, a membrane protein, and a nucleoprotein. Among them, spike protein is the most important surface membrane protein of coronavirus.